Key result
A vial-sparing antithrombin III protocol yielded similar median therapeutic heparin levels compared to a weight-based protocol (60.7% vs 56.5%; p=0.170) while significantly reducing costs.
Why the study?
Antithrombin III administration and dosing practices vary between ECMO centers in pediatric patients supported by extracorporeal membrane oxygenation.
Does a vial-sparing antithrombin III protocol maintain heparin efficacy and safety while reducing costs compared to a weight-based protocol in pediatric ECMO patients?
Cohort (n=47)
No
Does a vial-sparing antithrombin III protocol maintain heparin efficacy and safety while reducing costs compared to a weight-based protocol in pediatric ECMO patients?
Absolute Event Rate: 60.7% vs 56.5%
p-value: p=0.170
A vial-sparing antithrombin III protocol in pediatric ECMO patients significantly reduces costs without compromising heparin efficacy or safety compared to a weight-based protocol.
May support cost savings with maintained heparin efficacy in pediatric ECMO; leaves open need for randomized confirmation.
Exogenous antithrombin III (AT3) may be administered to pediatric patients supported by extracorporeal membrane oxygenation (ECMO) to achieve a greater systemic response to heparin. Antithrombin III administration and dosing practices vary between ECMO centers. This study compared the outcomes of two different AT3 replacement protocols used by a single pediatric ECMO center for 47 patients between December 2013 and August 2021. In May 2016, a weight-based continuous infusion protocol (WBP) was transitioned to a vial-sparing protocol (VSP) as a cost-saving measure. No difference was observed in the percentage of heparin monitoring levels within goal range, with a median of 56.5% therapeutic levels on the WBP compared with a median of 60.7% on the VSP ( p = 0.170). No significant differences were observed in amount of exogenous blood products administered, number of hemorrhagic or thrombotic events, number of mechanical failures, or number of circuit changes required. The VSP resulted in fewer AT3 dispenses ( p < 0.001) and units dispensed ( p = 0.005), resulting in a significant median cost reduction from $15,610.62 on the WBP to $7,765.56 on the VSP ( p = 0.005). A vial-sparing AT3 replacement protocol resulted in significant cost savings with similar efficacy and safety outcomes.
No takes yet. Share an insight, caveat, or question.
Young et al. (2023) conducted a cohort in Pediatric patients supported by extracorporeal membrane oxygenation (ECMO) (n=47). Vial-sparing antithrombin III replacement protocol vs. Weight-based continuous infusion protocol was evaluated on Percentage of heparin monitoring levels within goal range (p=0.170). A vial-sparing antithrombin III protocol yielded similar median therapeutic heparin levels compared to a weight-based protocol (60.7% vs 56.5%; p=0.170) while significantly reducing costs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: